| Lora Zoe Silverman, MD | |
|
1900 Wealthy St Se, Suite 180, Grand Rapids, MI 49506-2969 | |
| (616) 774-8501 | |
| (616) 774-8595 |
| Full Name | Lora Zoe Silverman |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 17 Years |
| Location | 1900 Wealthy St Se, Grand Rapids, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023214822 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 4301090627 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Spectrum Health | Grand rapids, MI | Hospital |
| Spectrum Health United Hospital | Greenville, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spectrum Health Primary Care Partners | 4587568647 | 1585 |
News Archive
According to two studies by the Centers for Disease Control and Prevention (CDC), African Americans in the U.S. continue to be disproportionately affected by stroke.
Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Researchers and doctors at Uppsala University, along with Swedish and international collaboration partners, have found gene variants that predict the risk of a serious adverse reaction to drugs used for the treatment of hyperthyroidism. The results are published in The Lancet Diabetes & Endocrinology.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
› Verified 9 days ago
| Entity Name | Spectrum Health Primary Care Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235188673 PECOS PAC ID: 4587568647 Enrollment ID: O20031121000091 |
News Archive
According to two studies by the Centers for Disease Control and Prevention (CDC), African Americans in the U.S. continue to be disproportionately affected by stroke.
Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Researchers and doctors at Uppsala University, along with Swedish and international collaboration partners, have found gene variants that predict the risk of a serious adverse reaction to drugs used for the treatment of hyperthyroidism. The results are published in The Lancet Diabetes & Endocrinology.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
› Verified 9 days ago
| Entity Name | Iha Health Services Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457408965 PECOS PAC ID: 2466351440 Enrollment ID: O20040108000355 |
News Archive
According to two studies by the Centers for Disease Control and Prevention (CDC), African Americans in the U.S. continue to be disproportionately affected by stroke.
Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Researchers and doctors at Uppsala University, along with Swedish and international collaboration partners, have found gene variants that predict the risk of a serious adverse reaction to drugs used for the treatment of hyperthyroidism. The results are published in The Lancet Diabetes & Endocrinology.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
› Verified 9 days ago
| Entity Name | Spectrum Health Hospitals |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558407189 PECOS PAC ID: 8921904764 Enrollment ID: O20040120000997 |
News Archive
According to two studies by the Centers for Disease Control and Prevention (CDC), African Americans in the U.S. continue to be disproportionately affected by stroke.
Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Researchers and doctors at Uppsala University, along with Swedish and international collaboration partners, have found gene variants that predict the risk of a serious adverse reaction to drugs used for the treatment of hyperthyroidism. The results are published in The Lancet Diabetes & Endocrinology.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lora Zoe Silverman, MD 100 Michigan St Ne, Suite 845, Grand Rapids, MI 49503-2560 Ph: () - | Lora Zoe Silverman, MD 1900 Wealthy St Se, Suite 180, Grand Rapids, MI 49506-2969 Ph: (616) 774-8501 |
News Archive
According to two studies by the Centers for Disease Control and Prevention (CDC), African Americans in the U.S. continue to be disproportionately affected by stroke.
Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Researchers and doctors at Uppsala University, along with Swedish and international collaboration partners, have found gene variants that predict the risk of a serious adverse reaction to drugs used for the treatment of hyperthyroidism. The results are published in The Lancet Diabetes & Endocrinology.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
› Verified 9 days ago
Dr. Navneet Singh Mander, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 E Paris Ave Se, Suite 230, Grand Rapids, MI 49546 Phone: 616-949-4340 | |
Robert Cuff, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4069 Lake Dr Se, S-312, Grand Rapids, MI 49546 Phone: 616-267-8700 Fax: 616-267-8247 | |
Dr. Cathryn Lynn Chadwick, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 221 Michigan St Ne Ste 400, Grand Rapids, MI 49503 Phone: 616-486-9600 Fax: 616-391-6428 | |
Benjamin Talbot, MD Surgery Medicare: Medicare Enrolled Practice Location: 4069 Lake Dr Se Ste 312, Grand Rapids, MI 49546 Phone: 616-267-8700 | |
Aamir Patel, MD Surgery Medicare: Medicare Enrolled Practice Location: 221 Michigan St Ne Ste 402, Grand Rapids, MI 49503 Phone: 616-391-1405 | |
Dr. Leon D Oostendorp, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 145 Michigan St Ne Ste 5500, Grand Rapids, MI 49503 Phone: 616-267-8540 |